scholarly journals Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure

Gut ◽  
1974 ◽  
Vol 15 (12) ◽  
pp. 993-998 ◽  
Author(s):  
B. G. Gazzard ◽  
M. L. Lewis ◽  
G. Ash ◽  
C. R. Rizza ◽  
E. Bidwell ◽  
...  
Hepatology ◽  
1996 ◽  
Vol 23 (6) ◽  
pp. 1507-1511 ◽  
Author(s):  
S Izumi ◽  
P G Langley ◽  
J Wendon ◽  
A J Ellis ◽  
R Pernambuco ◽  
...  

The Lancet ◽  
1974 ◽  
Vol 303 (7857) ◽  
pp. 521-524 ◽  
Author(s):  
S.P. Wilkinson ◽  
B.G. Gazzard ◽  
V. Arroyo ◽  
Helen Moodie ◽  
Roger Williams

Blood ◽  
2002 ◽  
Vol 100 (1) ◽  
pp. 143-147 ◽  
Author(s):  
Christopher B. Doering ◽  
Cassandra D. Josephson ◽  
Heather N. Craddock ◽  
Pete Lollar

Abstract Fulminant hepatic failure (FHF) in humans produces a bleeding diathesis due in large part to a reduction in the biosynthesis of liver-derived coagulation factors. Remarkably, factor VIII procoagulant activity is elevated in most of these patients despite widespread liver cell death. FHF can be modeled in mice by administration of azoxymethane, the active ingredient found in cycad palm nuts. We compared the expression of factor VIII to other hepatic hemostatic factors in azoxymethane-induced murine FHF. Mice displayed dose-dependent decreases in all coagulation factor activities measured, including factors V, VII, VIII, and IX. At the highest dose of azoxymethane (50 μg/g body weight), factor VIII activity in plasma decreased by 98% within 36 hours after treatment, which was associated with an 80% reduction in hepatic factor VIII messenger RNA (mRNA). In contrast, factor VIII mRNA levels in spleen, kidney, and lung tissue of azoxymethane-treated mice were unchanged. Cellular damage in these mice appeared to be limited to hepatocytes as evident by histologic examination. This finding is supported by 2 observations. First, hepatic mRNA levels of von Willebrand factor, which is synthesized by liver sinusoidal endothelial cells but not hepatocytes, were unchanged. Second, von Willebrand factor was detected antigenically in liver sections of azoxymethane-treated mice by immunofluorescence. These results indicate that the contribution of the liver to factor VIII biosynthesis is not replaced or significantly supplemented by other tissues in this model of FHF.


2018 ◽  
Vol 22 (4) ◽  
Author(s):  
Ewa Sikora ◽  
Paweł Łaguna ◽  
Michał Matysiak

Haemophilia is congenital with haemorrhagic diathesis due to deficiency of VIII or IX o coagulation factor, which is manifested by an increased tendency to bleeds. The therapeutic procedure during bleeding is intravenous administration of missing IX or VIII coagulation factor. The article presents a diagram of emergency procedures during bleeding in different locations. When discussing these cases, we would like to emphasize that, regardless of the type of bleeding or injury, correct treatment is first and foremost substitution of the missing coagulation factor and then of imaging and laboratory diagnostics. Delayed administration of a factor concentrate may cause a risk to the patient's life.


2001 ◽  
Vol 120 (5) ◽  
pp. A257-A257
Author(s):  
N SHAMUGAM ◽  
R AMARO ◽  
E MOLINA ◽  
L RAEZ

Sign in / Sign up

Export Citation Format

Share Document